SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

You may be eligible if

• Patients with pathologically confirmed selected tumor types (at site or centrally);
• Mandatory availability of adequate human biological material (HBM);
• Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements;
• Age ≥ 12 years;
• Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule;
• Written informed consent according to applicable legal and ethical requirements;